Margaret Kaczor
Stock Analyst at William Blair
(0.58)
# 3,876
Out of 4,837 analysts
24
Total ratings
35.71%
Success rate
-17.28%
Average return
Main Sectors:
Stocks Rated by Margaret Kaczor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STAA STAAR Surgical Company | Downgrades: Market Perform | n/a | $19.25 | - | 2 | Feb 12, 2025 | |
| CVRX CVRx, Inc. | Upgrades: Outperform | n/a | $6.99 | - | 3 | Jan 14, 2025 | |
| CBLL CeriBell | Initiates: Outperform | n/a | $18.17 | - | 1 | Nov 5, 2024 | |
| STIM Neuronetics | Downgrades: Market Perform | n/a | $4.29 | - | 4 | Aug 12, 2024 | |
| INGN Inogen | Upgrades: Outperform | n/a | $6.27 | - | 5 | Feb 15, 2024 | |
| SKIN The Beauty Health Company | Downgrades: Market Perform | n/a | $1.69 | - | 2 | Nov 14, 2023 | |
| DVA DaVita | Downgrades: Market Perform | n/a | $145.77 | - | 2 | Sep 11, 2019 | |
| MDT Medtronic | Assumes: Market Perform | n/a | $86.37 | - | 1 | Jun 6, 2018 | |
| ABT Abbott Laboratories | Upgrades: Outperform | n/a | $135.20 | - | 3 | Jan 25, 2018 | |
| DXCM DexCom | Initiates: Outperform | n/a | $87.34 | - | 1 | Apr 27, 2017 |
STAAR Surgical Company
Feb 12, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $19.25
Upside: -
CVRx, Inc.
Jan 14, 2025
Upgrades: Outperform
Price Target: n/a
Current: $6.99
Upside: -
CeriBell
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $18.17
Upside: -
Neuronetics
Aug 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.29
Upside: -
Inogen
Feb 15, 2024
Upgrades: Outperform
Price Target: n/a
Current: $6.27
Upside: -
The Beauty Health Company
Nov 14, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.69
Upside: -
DaVita
Sep 11, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $145.77
Upside: -
Medtronic
Jun 6, 2018
Assumes: Market Perform
Price Target: n/a
Current: $86.37
Upside: -
Abbott Laboratories
Jan 25, 2018
Upgrades: Outperform
Price Target: n/a
Current: $135.20
Upside: -
DexCom
Apr 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $87.34
Upside: -